A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Inclusion Criteria
*  Documented diagnosis of multiple Mmyeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
*  Received at least 4 classes of MM treatment \[including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and anti-B cell maturation antigen (BCMA) therapy\], and at least 3 prior lines of therapy (LOT).
*  Documented disease progression during or after their last anti-myeloma regimen as per IMWG.
*  Participants must have measurable disease during screening.
*  Have measurable disease during screening.
*  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria
*  Active or history of central nervous system involvement with MM.
*  Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.
*  Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.
*  Other protocol-defined Inclusion/Exclusion criteria apply.